Drug Utilization Study and Adverse Drug Reaction Reporting among Patients Using Anticoagulants in a Tertiary Care Teaching Hospital
Drug utilization (DU) is systematic regulatory approach designed to identify diversity of drugs use and to evaluate the rational use of medicines in population. Anticoagulants are drugs used to avoid thrombus extension and embolic consequences with associated risks related to their administration. Objectives: The objectives of the present study were to evaluate the drug prescription pattern of anticoagulants, observe and report drug interactions and adverse drug reactions among patients using anticoagulants. Method: Utilization of anticoagulant drugs was evaluated in 50 patients from 4 wards (dialysis, medicine, orthopedic and intensive-care unit) of a tertiary care teaching hospital in a cross-sectional, prospective study conducted for 4 months i.e. from 1st January 2018 to 30th April 2018. Results: LMWH (enoxaparin) was the maximum preferred parenteral anticoagulant prescribed to 31 % of patients as prophylaxis for deep vein thrombosis followed by heparin. 14(28%) of total population were administered combination therapy and 36 (72%) patients received only one anticoagulant drug during hospitalization. The most prescribed drug combination was enoxaparin+warfarin followed by enoxaparin+acenocoumarol. For discharge medicines, 14 patients were prescribed oral anticoagulants; 9 (64.3%) patients were prescribed with warfarin and the remaining 5 (35.7%) patients were given acenocoumarol. 28(56%) patient’s laboratory tests were evaluated for parameters like prothrombine time (PT) and international normalized ratio (INR). In the remaining 22(44%) patients, the above tests were not performed. Sixteen drug interactions were identified, ten were pharmacodynamics and the rest six were pharmacokinetic interactions. Three adverse drug reactions were reported during the study. The need for dosage adjustment in different diagnostic situations or specific populations is very crucial. Conclusion: The therapy with these drugs needs to be cost effective and reduce the complications associated with their use.
Keywords: Anticoagulants, Drug utilization evaluation, Drug interactions.
2. Naqvi SE, Haseen MA, Beg MH, Ali E and Khan T: Deep vein thrombosis: An experience of 25 years from north India. Indian Journal of Vascular and Endovascular Surgery 2016 Jan 1; 3(1):2.
3. Geerts WH and Pineo GF: prevention of thromboembolism. The seventh ACCP Conference on antithrombotic and thrombolytic 2004; 126(3):338S–400S.
4. Imberti D, Becattini C, Bernardi E, Camporese G, Cuccia C, Dentali F and Paretti D: Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban. Internal and Emergency Medicine 2018 Oct 1; 13(7):1037-49.
5. Cestac P, Bagheri H, Lapeyre-Mestre M, Sié P, Fouladi A, Maupas E, Léger P, Fontan B, Massip P and Montastruc JL: Utilization and safety of low molecular weight heparins. Drug Safety 2003 Mar 1; 26(3):197-207.
6. Singh V, Gopinath K, Behzadpour A and Meera NK: Anticoagulant utilization evaluation in a Tertiary Care Teaching Hospital: An observational prospective study in medical in patients. Indian Journal of Pharmacy Practice 2015 Apr; 8(2):61.
7. Koren‐Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S and Golik A: Early onset of hyperkalemia in patients treated with low molecular weight heparin: A prospective study. Pharmacoepidemiology and Drug Safety 2004 May; 13(5):299-302.
8. Schrader J, Valentin R, Tönnis HJ, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Köstering H and Quellhorst E: Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney International 1985 Nov 1; 28(5): 823-9.
9. Jaffin BW, Bliss CM and Lamont JT: Significance of occult gastrointestinal bleeding during anticoagulation therapy. The American Journal of Medicine 1987 Aug 1; 83(2): 269-72.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).